| Similar Articles |
|---|
 |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life.   |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
January 25, 2007
Brian Gorman |
Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year. |
The Motley Fool
April 20, 2004
Brian Gorman |
PPD's New Possibilities The royalty stream from dapoxetine could significantly boost earnings. |
InternetNews
September 1, 2006
Clint Boulton |
Equity Group Offers $1.3B for Intergraph Intergraph Corporation, a leading maker of mapping and visualization software, agreed to be acquired for $1.3 billion by an investor group led by Hellman & Friedman LLC and Texas Pacific Group. |
The Motley Fool
August 25, 2006
Brian Gorman |
California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
March 20, 2006
Brian Gorman |
Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
July 15, 2004
Brian Gorman |
Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%. |
The Motley Fool
October 21, 2005
Brian Gorman |
Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet. |
InternetNews
April 25, 2005
Clint Boulton |
Equity Firm to Buy DoubleClick for $1.1B DoubleClick CEO will step down after the online advertising and marketing concern accepts a buyout from Hellman & Friedman LLC. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
January 27, 2005
Brian Gorman |
Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
The Motley Fool
April 25, 2005
Brian Gorman |
Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar. |
The Motley Fool
April 28, 2006
Brian Gorman |
Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note. |
The Motley Fool
May 21, 2009
Selena Maranjian |
Make Money With or Without Health-Care Reform While there's obviously a lot at stake in the health-care discussions going on in Washington, you don't have to guess right about what's going to happen in order to profit from the industry. |
The Motley Fool
November 8, 2010
Esterhuizen & Sellitti |
6 Executive Insiders Expecting a Health-Care Rally With the economy continuing to struggle, not to mention the passage of the health-care bill, the sector's expecting a lot of near-term volatility. |
The Motley Fool
January 21, 2010
Dan Caplinger |
Doing This Will Just Drive You Crazy Short-term stock movements are unpredictable. |
Chemistry World
November 12, 2014
Phillip Broadwith |
Labcorp to buy Covance and enter contract research Medical diagnostics specialist Labcorp has agreed to buy contract research organization Covance for around $6 billion. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
April 28, 2005
Brian Gorman |
PPD Branches Out The company, which concentrates on running clinical trials for pharmaceutical and biotech clients is right in diversifying, but its strategy carries its own risk. |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
January 27, 2011
Seth Jayson |
Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors. |
The Motley Fool
April 18, 2006
Brian Gorman |
PPD Develops Solid Growth The contract research firm cashes in on its core business. Investors celebrated Pharmaceutical Product Development's latest earnings release today by sending the stock up more than 9% in recent trading. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
The Motley Fool
October 17, 2006
Tom Taulli |
Open Solutions Is Going Dot-Com This nice growth business that provides software to financial institutions is so nice that two top private equity firms will buy it out. Investors, take note. |
The Motley Fool
August 11, 2006
Brian Gorman |
PAREXEL Takes It Up a Notch The company reported higher profitability in the fourth quarter, and management expects the trend to continue. Investors, is this worth a closer look? |
The Motley Fool
October 26, 2005
Stephen D. Simpson |
Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it. |
The Motley Fool
April 20, 2011
Brandon Glenn |
Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle. |
The Motley Fool
January 10, 2006
Stephen D. Simpson |
Can ICON Be a Paragon of Growth? The clinical research organization specialist and stock have recovered from some troubles, but do current valuations leave much on the table? |
